You are here: Industry Insights > Prostate Cancer

News List

LYNPARZA (olaparib) get three new approvals in Japan expresspharma
December 29, 2020
Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials.
Sheffield University gets £3.1 mn for trials to better bladder, prostate cancer diagnosis, treatment expresspharma
November 19, 2020
The two trials are part of a wider £8.3 million funding boost for new research programmes across Yorkshire.
Farrer Park Hospital Steps Up Prostate Cancer Treatment with Lutetium-177 PSMA Therapy prnasia
November 10, 2020
Farrer Park Hospital announced today the availability of Lutetium-177 Prostate Specific Membrane Antigen Therapy, a treatment for advanced prostate cancer.
NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer pharmaceutical-business-review
November 10, 2020
NanOlogy LLC has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.
Bayer’s Nubeqa wins NICE prostate cancer backing pharmatimes
October 29, 2020
Bayer’s Nubeqa has scored backing from the UK’s National Institute for Health and Care Excellence (NICE) for treating non-metastatic castration-resistant prostate cancer (nmCRPC).
BDR Pharma launches 80mg of Enzalutamide for prostate cancer treatment expresspharma
September 22, 2020
It reduces the pill burden and expected to increase the patient compliance.
First patient in treatment in RhoVac's clinical phase IIb study in Sweden prnasia
September 18, 2020
RhoVac AB ("RhoVac") announces today, on September 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac").
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer pharmaceutical-business-review
July 06, 2020
Exelixis, Inc. announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been ...
NICE sticks to Zytiga rejection pharmatimes
June 29, 2020
NICE will not be recommending Janssen's Zytiga (abiraterone acetate) with prednisone or prednisolone plus androgen deprivation therapy (ADT), within its marketing authorisation , for treating newly diagnosed high-risk metastatic ...
Novel prostate cancer drug formulation could improve drug’s efficacy europeanpharmaceuticalreview
June 23, 2020
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page